ABSTRACT
Although recent accumulative data reveal the clinicopathogenesis of regression in methotrexate-induced lymphoproliferative disorders (MTX-LPDs), the precise understanding including this category remains controversial. In this study, we analyzed 62 patients with MTX-LPD. Forty-three patients showed regression (Reg group), with high rates of Hodgkin lymphoma (HL) and LPD (90 and 88%, respectively). Among the 43 patients of the Reg group, 14 patients (33%) relapsed. The median duration before relapse in the Reg group was 10.6 months. Although the difference of OS between the Reg and Non-Reg groups was not significantly different, relapse-free patients in the Reg group had a superior overall survival (OS). MTX duration had a significant impact on Epstein-Barr virus (EBV) infection (p = .00131). Furthermore, EBV infection was significantly related to clinical manifestations, including spleen invasion, in the regression phenomenon. Some human leukocyte antigens (HLA) alleles might affect MTX-LPD development via EBV infection, although A*2402 and DRB1*0405 might be affected as fundamental factors.
Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Epstein-Barr Virus Infections/complications , Herpesvirus 4, Human/isolation & purification , Lymphoproliferative Disorders/pathology , Methotrexate/adverse effects , Adult , Aged , Aged, 80 and over , Epstein-Barr Virus Infections/virology , Female , Follow-Up Studies , Humans , Lymphoproliferative Disorders/chemically induced , Lymphoproliferative Disorders/virology , Male , Middle Aged , Prognosis , Remission Induction , Survival RateABSTRACT
Recently, attention has been focused on methotrexate-induced lymphoproliferative disease (MTX-LPD), and atypical phenotypes are occasionally documented. We encountered two patients with rheumatoid arthritis (RA) who were diagnosed with non-specific LPD (LPD-nos). Biopsy samples were not obtained during the initial examination when the LPD development was discovered, and the patients achieved a complete response after MTX cessation (case 1) or steroid pulse therapy (case 2). However, the tumors flared up 1.5 years later, and LPD-nos was determined following biopsies of the lymph node (LN, case 1) and liver (case 2). Prednisolone was subsequently administered instead of chemotherapy; however, multiple masses, including in the spine (case 1), and severe icterus with liver dysfunction (case 2) were exacerbated within a few months. Although the re-biopsy of LN proved the presence of HL and radiation followed by aggressive chemotherapy rescued the patient (case 1), the superficially accessible biopsy site was not found, and autopsy finally revealed HL (case 2). In both cases, the underlying pathogenesis along with the B symptoms and laboratory abnormalities suggested MTX-LPD, HL in particular. Therefore, even if the pathological diagnosis does not confirm the specific LPD subtype, the administration of aggressive chemotherapy should be considered if the LPD activity flares severely.
Subject(s)
Arthritis, Rheumatoid/complications , Hodgkin Disease/diagnosis , Lymphoproliferative Disorders/diagnosis , Antineoplastic Agents/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , Female , Hodgkin Disease/drug therapy , Humans , Lymphoproliferative Disorders/chemically induced , Lymphoproliferative Disorders/drug therapy , Male , Methotrexate/adverse effects , Middle Aged , Prednisolone/therapeutic use , Recurrence , Remission Induction/methodsABSTRACT
Thrombopoietin receptor (TPO-R) agonists have been shown to be effective in refractory chronic immune thrombocytopenia (ITP); however, their efficacy in patients under critical care is not known. We report the case of a female patient with a newly diagnosed ITP who experienced severe bleeding from an external wound. The patient was administered the standard treatments for ITP, which are high-dose intravenous immunoglobulin (IVIg) and corticosteroids. However, following failure of these treatments, we administered romiplostim on day 6 after the onset of ITP. On day 6 after the initiation of romiplostim, there was improvement in platelet count and bleeding tendency. We were subsequently able to perform a splenectomy successfully. The efficacy of TPO-R agonists in ITP has been reported in several situations, including before surgery in an ITP patient; however, the use of TPO-R for arterial bleeding with shock has not been reported. To our knowledge, the present article is a rare case report of the use of a TPO-R agonist in a patient with critical artery injury. Our data suggest that the early use of romiplostim is effective in emergency cases of newly diagnosed ITP with life-threatening bleeding, which is refractory to standard treatment.
Subject(s)
Carotid Artery Injuries/complications , Hemorrhage/complications , Purpura, Thrombocytopenic, Idiopathic/complications , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Receptors, Fc/therapeutic use , Receptors, Thrombopoietin/agonists , Recombinant Fusion Proteins/therapeutic use , Thrombopoietin/therapeutic use , Aged , Carotid Artery Injuries/blood , Carotid Artery Injuries/drug therapy , Female , Hemorrhage/blood , Hemorrhage/drug therapy , Humans , Platelet Count , Purpura, Thrombocytopenic, Idiopathic/bloodABSTRACT
Primary cardiac lymphoma is extremely rare and is associated with a poor prognosis. In most cases, cardiac involvement occurs as a late symptom and the diagnosis is thus delayed. We herein report a 35-year-old woman with cardiac diffuse large B-cell lymphoma (DLBCL) with breast infiltration. The patient was admitted to our hospital based on an initial presentation with dyspnea on exertion, chest pain, and a hard mass of the left breast. Echocardiography revealed a mass in the right atrium wall and interatrial septum, and massive pericardial effusion. ECG showed atrioventoricular block. We promptly performed a needle biopsy of the breast mass, which showed CD5-positive DLBCL, non-GCB type. The serum HIV reaction was negative. We thus diagnosed this patient as having cardiac and breast CD5-positive DLBCL, stage IVA, based on the massive pericardial effusion. The patient's prognosis was apparently poor. Therefore, she received 3 cycles of R-CHOP chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT), resulting in a complete response. In general, cardiac lymphoma is associated with high mortality and has a poor prognosis. This case demonstrates that rapid and appropriate diagnosis, and immediate intensive chemotherapy followed by PBSCT might be necessary for the treatment of extranodal lymphoma indicative of a poor prognosis.
Subject(s)
Breast Neoplasms/therapy , Heart Neoplasms/therapy , Lymphoma, Large B-Cell, Diffuse/therapy , Pericardial Effusion/therapy , Adult , Breast Neoplasms/complications , Breast Neoplasms/diagnosis , Female , Heart Neoplasms/complications , Heart Neoplasms/diagnosis , Heart Neoplasms/pathology , Humans , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/pathology , Neoplasm Staging , Pericardial Effusion/diagnosis , Pericardial Effusion/etiology , Peripheral Blood Stem Cell Transplantation , Treatment OutcomeSubject(s)
Arthritis, Rheumatoid/complications , Immunosuppressive Agents/adverse effects , Leukemia, Myeloid/etiology , Lymphoproliferative Disorders/chemically induced , Methotrexate/adverse effects , Neoplasms, Second Primary/etiology , Bone Marrow/pathology , Fatal Outcome , Female , Humans , Immunohistochemistry , Immunosuppressive Agents/therapeutic use , In Situ Hybridization, Fluorescence , Leukemia, Myeloid/diagnosis , Lymphoproliferative Disorders/diagnosis , Methotrexate/therapeutic use , Middle Aged , Neoplasms, Second Primary/diagnosisABSTRACT
Despite numerous attempts to uncover the mechanism of other iatrogenic immunodeficiency-associated lymphoproliferative diseases (OIIA-LPDs), this mechanism remains poorly understood, especially in rheumatoid arthritis (RA) patients. We analyzed the data on 23 patients with LPDs and RA. Patients were categorized into three groups according to whether they had methotrexate (MTX); MTX-regressive LPDs, MTX-persistent LPDs or other drugs-mediated LPDs. The LPDs seen in OIIA-LPDs-RA might have a unique behavior to think about several rare phenotypes. The overall survival of all patients was 74% at 5 years, and those of the three groups were 100%, 64% and 60%, respectively. Among the 6 patients who died, 4 had LPDs that were detected late, and thus adequate treatment was not given. In addition, several patients with diffuse large B cell lymphoma with a complex karyotype achieved complete remission (CR). Only one among the 17 patients who achieved CR relapsed. OIIA-LPDs-RA appeared to have a better prognosis than other more common types of lymphomas. Regarding RA treatment, various anti-RA drugs were given to the patients after developing LPDs, including MTX, but no recurrent patients were documented.
Subject(s)
Arthritis, Rheumatoid/drug therapy , Immunocompromised Host , Lymphoproliferative Disorders/pathology , Methotrexate/therapeutic use , Adult , Aged , Aged, 80 and over , Antigens, CD20/metabolism , Antirheumatic Agents/adverse effects , Antirheumatic Agents/therapeutic use , Chromosome Aberrations , Epstein-Barr Virus Infections/pathology , Epstein-Barr Virus Infections/virology , Female , Flow Cytometry , Humans , Immunohistochemistry , Karyotype , Ki-1 Antigen/metabolism , Lymphoproliferative Disorders/chemically induced , Lymphoproliferative Disorders/therapy , Male , Methotrexate/adverse effects , Middle Aged , Prognosis , Survival AnalysisABSTRACT
Bortezomib is a potent agent for multiple myeloma (MM); however, severe treatment-related toxicities such as peripheral neuropathy have been observed in conjunction with its use. In this study, we present the cases of 9 patients with refractory MM whose administration schedule was modified from twice weekly to an interval of once weekly or longer mainly due to adverse events. The average duration from diagnosis to the time of bortezomib induction was 56 months. The schedule was changed to the modified administration according to the physician's discretion. The average duration of modified treatment was 16 months. Six patients with IgG or IgA subtype showed more than a minor response. One patient with BJP had stable disease for 3 years, and the other BJP-type patient with extramedullary plasmacytomas showed remarkable tumor regression. The treatment-related toxicities of this strategy were mild and tolerable. To our knowledge, this is the first report of the administration of bortezomib at intervals longer than once weekly.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Boronic Acids/administration & dosage , Drug Resistance, Neoplasm , Multiple Myeloma/drug therapy , Pyrazines/administration & dosage , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Boronic Acids/adverse effects , Bortezomib , Drug Administration Schedule , Drug Resistance, Neoplasm/drug effects , Female , Humans , Male , Middle Aged , Multiple Myeloma/mortality , Pyrazines/adverse effects , Remission Induction , Survival Analysis , Treatment OutcomeABSTRACT
An 83-year-old woman had been suffering from palpitations and fatigue for a month. An annual screening test revealed an increased WBC count so she was referred to our hospital. CBC showed extremely elevated WBC count (186,300/microl), in which the population of blastic eosinophils was over 90%. The eosinophils expressed CD7/13/33/34/DR, and the karyotype demonstrated 47,XX,+8. The fusion gene of FIP1-LP/PDGFRalpha in peripheral blood was negative. As plural effusion due to the underlying disease progressively worsened, she was given prednisolone and hydroxyurea, but the effect was limited. Steroid pulse therapy and imatinib (100 mg/day) were administrated. As a result, a prompt response was observed. The WBC count rapidly decreased, but tumor lysis syndrome led to acute renal failure and disseminated intravasucular coagulation appeared. Supportive therapies such as artificial dialysis and transfusions were conducted, but unfortunately she died because of alveolar hemorrhage.
Subject(s)
Leukemia, Eosinophilic, Acute/complications , Leukemia, Eosinophilic, Acute/drug therapy , Methylprednisolone/adverse effects , Piperazines/adverse effects , Pyrimidines/adverse effects , Tumor Lysis Syndrome/etiology , Acute Kidney Injury/etiology , Aged, 80 and over , Benzamides , Disseminated Intravascular Coagulation/etiology , Drug Synergism , Fatal Outcome , Female , Humans , Hypereosinophilic Syndrome/complications , Imatinib Mesylate , Methylprednisolone/administration & dosage , Piperazines/administration & dosage , Pleural Effusion/etiology , Pulse Therapy, Drug , Pyrimidines/administration & dosageABSTRACT
Rheumatoid arthritis (RA) is an autoimmune disease mediated by inflammatory processes mainly at the joints. Recently, awareness of Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder (T-LPD) has been heightened for its association with methotraxate usage in RA patients. In the contrary, acute myeloid leukemia with multilineage dysplasia (AML-MLD) has never been documented to be present concomitantly with the above two conditions. In this report we present a case of an autopsy-proven co-existence of AML-MLD and EBV-associated T-LPD in a patient with RA.
Subject(s)
Arthritis, Rheumatoid/complications , Epstein-Barr Virus Infections/complications , Leukemia, Myeloid, Acute/complications , Lymphoproliferative Disorders/complications , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/immunology , Cell Lineage , Diagnosis , Epstein-Barr Virus Infections/diagnosis , Humans , Leukemia, Myeloid, Acute/diagnosis , Leukemia, Myeloid, Acute/pathology , Lymphoproliferative Disorders/diagnosis , Male , Middle Aged , T-Lymphocytes/pathologyABSTRACT
We here report the case of a young Japanese woman diagnosed with chronic active Epstein-Barr virus (EBV) infection. Intensive therapy with the CHOP regimen was partially able to control virus expansion, but various central nervous system symptoms appeared and gradually progressed. EBV-encoded RNA, detected using in situ hybridization, disclosed the presence of EBV in liver and bone marrow tissue, and real-time PCR revealed the presence of EBV in the cerebrospinal fluid (CSF) and serum. CD3+CD4+CD8-CD56- T-cell expansion in the peripheral blood (PB) and CSF was also observed. Atrophic brain changes were progressive, and the patient died of central nervous system disturbance and pulmonary hemorrhage a year after diagnosis. Autopsy revealed that EBV-infected T lymphocytes with a phenotype similar to those seen in PB and CSF had infiltrated multiple organs: the lymph nodes, bone marrow, endocardium, pericardium, myocardium, spleen, liver, and spinal cord. There have been few previous reports of severe degenerative changes in the myocardium, liver, and spinal cord in patients with EBV infection. Although EBV occasionally infiltrates the central nervous system and brain, atrophic changes mediated by EBV are rare. The autopsy results of this case suggest the possibility of EBV-mediated, severe degenerative changes in multiple organs.
Subject(s)
CD4-Positive T-Lymphocytes/pathology , Epstein-Barr Virus Infections/pathology , Herpesvirus 4, Human , Liver/pathology , Myocardium/pathology , Spinal Cord/pathology , Spleen/pathology , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Autopsy , CD4-Positive T-Lymphocytes/immunology , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Epstein-Barr Virus Infections/cerebrospinal fluid , Epstein-Barr Virus Infections/drug therapy , Epstein-Barr Virus Infections/immunology , Female , Humans , Immunohistochemistry , Liver/immunology , Liver/metabolism , Liver/virology , Myocardium/immunology , Myocardium/metabolism , Prednisone/administration & dosage , RNA, Viral/metabolism , Spinal Cord/immunology , Spinal Cord/metabolism , Spinal Cord/virology , Spleen/immunology , Spleen/metabolism , Spleen/virology , Vincristine/administration & dosageABSTRACT
Basophils play an important role in allergic inflammation and are pathologically related to hematological disturbances, such as iron deficiency anemia and myeloproliferative disorders; however, they are only rarely encountered in lymphoid malignancies. Here, we report the case of a 33-year-old man with a bulky mass of the small intestine, multiple paraaortic lymphoadenopathy, pleural effusion, and ascites, who was diagnosed as a case of de novo CD5+ diffuse large B cell lymphoma (DLBCL). This patient showed a marked elevation of the basophil count in the peripheral blood, which appeared to run in parallel with the tumor burden. High dose chemotherapy followed by autologous peripheral blood cell transplantation yielded complete remission, and the patient has remained disease free for 5 years. To the best of our knowledge, this is the first report of a case of de novo CD5+ DLBCL showing marked elevation of the PB basophil count.